Evaluation of two dynamic in vitro models simulating fasted and fed state conditions in the upper gastrointestinal tract (TIM-1 and tiny-TIM) for investigating the bioaccessibility of pharmaceutical compounds from oral dosage forms

International Journal of Pharmaceutics

Volumn 498, Issue 1-2, 2016, Pages 178-186

  Verwei, Miriam ^a   Minekus, Mans ^a   Zeijdner, Evelijn ^a   Schilderink, Ronald ^a   Havenaar, Robert ^a  

^a TNO   (Netherlands)

Author keywords

Food effect; In vitro gastrointestinal model; Oral dosage form; Pharmaceutical bioaccessibility; TIM system

Indexed keywords

CIPROFLOXACIN; FENOFIBRATE; NANOCARRIER; NIFEDIPINE; POSACONAZOLE; UNCLASSIFIED DRUG; DRUG;

ADULT; ANATOMIC MODEL; ARTICLE; COMPUTER SIMULATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG RELEASE; EVALUATION STUDY; GENERAL DEVICE; GENERAL MEDICAL DEVICE; HUMAN; HUMAN VERSUS NONHUMAN DATA; IN VITRO STUDY; NANOPHARMACEUTICS; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; SMALL INTESTINE; STOMACH; TIM 1 SYSTEM; TIME TO MAXIMUM PLASMA CONCENTRATION; TINY TIM SYSTEM; UPPER GASTROINTESTINAL TRACT; BIOAVAILABILITY; BIOLOGICAL MODEL; DIET RESTRICTION; DRUG EFFECTS; EATING; LIPID DIET; MEDICINAL CHEMISTRY; METABOLISM; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; POSTPRANDIAL STATE; PRECLINICAL STUDY; PROCEDURES;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; COMPUTER SIMULATION; DIET, HIGH-FAT; DRUG EVALUATION, PRECLINICAL; EATING; FASTING; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; POSTPRANDIAL PERIOD; UPPER GASTROINTESTINAL TRACT;

EID: 84951206395     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.11.048     Document Type: Article

References (39)

1. M. Ahmad, T. Ahmad, R.A. Sultan, and G. Murtaza Pharmacokinetic study of nifedipine in healthy adult male human volunteers Trop. J. Pharm. Res. 8 5 2009 385 391
2. M. Anschütz, M. Wonnemann, B. Schug, C. Toal, F. Donath, A. Pontius, K. Pauli, E. Brendel, and H.H. Blume Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration Int. J. Clin. Pharmcol. Ther. 48 2010 158 170
3. M.A.K. Azad, A. Ullah, A.H.M.M. Latif, and A. Hasnat Bioequivalence and pharmacokinetic study of two oral formulations of ciprofloxacin tablets in healthy male volunteers J. Appl. Res. 7 2007 150 157
4. R. Barker, B. Abrahamsson, and M. Kruusmägi Application and validation of an advanced gastro-intestinal in vitro model for evaluation of drug product performance in pharmaceutical development J. Pharm. Sci. 103 11 2014 3704 3712
5. S. Blanquet, E. Zeijdner, E. Beyssac, J.-P. Meunier, S. Denis, R. Havenaar, and M. Alric A dynamic artificial gastrointestinal system for studying the behavior of orally administered drug dosage forms under various physiological conditions Pharm. Res. 21 4 2004 585 591
6. H. Bode, E. Brendel, G. Ahr, U. Fuhr, S. Harder, and A.H. Staib Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of C- and C-nifedipine Eur. J. Clin. Pharmacol. 50 1996 195 201
7. J. Brouwers, B. Anneveld, G.J. Goudappel, G. Duchateau, P. Annaert, P. Augustijns, and E. Zeijdner Food-dependent disintegration of immediate release fosamprenavir tablets: in vitro evaluation using magnetic resonance imaging and a dynamic gastrointestinal system Eur. J. Pharm. Biopharm. 77 2011 313 319
8. R. Courtney, D. Wexler, E. Radwanski, J. Lim, and M. Laughlin Effect of food on the releative bioavailability of two oral formulations of posaconazole in healthy adults Br. J. Clin Pharmacol. 57 2 2003 218 222
9. R. Courtney, E. Radwanski, J. Lim, and M. Laughlin Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men Antimicrob. Agents Chemother. 48 2004 804 808
10. S.E. David, M.M. Strozyk, and T.A. Naylor Using TNO gastro-intestinal model (TIM-1) to screen potential formulations for a poorly soluble development compound J. Pharm. Pharmacol. 62 2010 1236 1237
11. P.A. Dickinson, R. Abu Rmaileh, L. Ashworth, R.A. Barker, W.M. Burke, C.M. Patterson, N. Stainforth, and M. Yasin An investigation into the utility of a multi-compartmental, dynamic, system of the upper gastrointestinal tract to support formulation development and establish bioequivalence of poorly soluble drugs AAPS J. 14 2 2012 196 205
12. FDA/CDER, 2002. Guidance for Industry. Food-Effect Bioavailability and Fed Bioequivalence Studies. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). December 2002 (annex 2).
13. T.S. Foster, S.R. Hamann, V.R. Richards, P.J. Bryant, D.A. Graves, and R.G. McAllister Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects J. Clin. Pharm. 23 1983 161 170
14. A. Franke, S. Teyssen, H. Harder, and M.V. Singer Effect of ethanol and some alcohol beverages on gastric emptying in humans Scand. J. Gastroenterol. 39 2004 638 644
15. A. Hanafy, H. Spahn-Langguth, G. Vergnault, P. Grenier, M. Tubic Grozdanis, T. Lenhardt, and P. Langguth Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug Adv. Drug Deliv. Rev. 59 2007 419 426
16. R. Havenaar, A. De Jong, M.J. Koenen, J. Van Bilsen, A.M. Janssen, E. Labij, and H.J.M. Westerbeek Digestibility of transglutaminase cross-linked caseinate versus native caseinate in an in vitro multi-compartmental model simulating young child and adult gastrointestinal conditions J. Agric. Food Chem. 61 31 2013 7636 7644
17. R. Havenaar, B. Anneveld, L.M. Hanff, S.N. De Wildt, B.A.E. De Koning, M.G. Mooij, J.P.A. Lelieveld, and M. Minekus In vitro gastrointestinal model (TIM) with predictive power, even for infants and children? Int. J. Pharm. 457 2013 327 332
18. B. Hens, J. Brouwers, M. Corsetti, and P. Augustijns Gastrointestinal behavior of nano- and microsized fenofibrate: in vivo evaluation in man and in vitro simulation by assessment of the permeation potential Eur. J. Pharm. Sci. 77 2015 40 47
19. G. Höffken, H. Lode, C. Prinzing, K. Borner, and P. Koeppe Pharmacokinetics of ciprofloxacin after oral and parenteral administration Antimicrob. Agents Chemother. 27 3 1985 375 379
20. N.A. Kasim, M. Whitehouse, C. Ramachandran, M. Bermejo, H. Lennernäs, A.S. Hussain, H.E. Junginger, S.A. Stavchansky, K.K. Midha, V.P. Shah, and G.L. Amidon Molecular properties of WHO essential drugs and provisional biopharmaceutical classification Mol. Pharm. 1 1 2003 85 96
21. C.H. Kleinbloesem, P. van Brummelen, J.A. van de Linde, P.J. Voogd, and D.D. Breimer Nifedipine: kinetics and dynamics in healthy subjects Clin. Pharmacol. Ther. 35 1984 742 749
22. E.S. Kostewicz, B. Abrahamsson, M. Brewster, J. Brouwers, J. Butler, S. Carlert, P.A. Dickinson, J. Dressman, R. Holm, S. Klein, J. Mann, M. McAllister, M. Minekus, U. Muenster, A. Müllertz, M. Verwei, M. Vertzoni, W. Weitschies, and P. Augustijns In vitro models for the prediction of in vivo performance of oral dosage forms Eur. J. Pharm. Sci. 57 1 2014 342 366
23. G. Krishna, A. Moton, L. Ma, M.M. Medlock, and J. McLeod Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers Antimicrob. Agents Chemother. 53 3 2009 958 966
24. B. Ledergerber, J.D. Bettex, B. Joos, M. Flepp, and R. Lüthy Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin Antimicrob. Agents Chemother. 27 3 1985 350 352
25. H. Lennernäs, L. Aarons, P. Augustijns, S. Beato, M. Bolger, K. Box, M. Brewster, J. Butler, J. Dressman, R. Holm, K. Julia Frank, R. Kendall, P. Langguth, J. Sydor, A. Lindsahl, M. McAllister, U. Muenster, A. Müllertz, K. Ojala, X. Pepin, C. Reppas, A. Rostami-Hodjegan, M. Verwei, W. Weitscies, C. Wilson, C. Karlsson, and B. Abrahamsson Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo Eur. J. Pharm. Sci. 57 2014 292 299
26. J.T. Lettieri, M.C. Rogge, L. Kaiser, R.M. Echols, and A.H. Heller Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses Antimicrob. Agents Chemother. 36 5 1992 993 996
27. H.-P. Lipp Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum riazole posaconazole: an overview Br. J. Clin. Pharm. 70 4 2010 471 480
28. M. Minekus, P. Marteau, R. Havenaar, and J.H.J. Huis in 't Veld A multi compartmental dynamic computer-controlled model simulating the stomach and small intestine Altern. Lab. Anim. (ATLA) 23 1995 197 209
29. M. Minekus, M.J.E. Smeets-Peeters, A. Bernalier, S. Marol-Bonnin, R. Havenaar, P. Marteau, M. Alric, G. Fonty, and J.H.J. Huis in 't Veld A computer-controlled system to simulate conditions of the large intestine with peristaltic mixing, water absorption and absorption of fermentation products Appl. Microb. Biotechnol. 53 1999 108 114
30. R. Murray, W. Bartoli, J. Stofan, M. Horn, and D. Eddy A comparison of the gastric emptying characteristics of selected sports drinks Int. J. Sport Nutr. 9 3 1999 263 274
31. T.A. Naylor, P.C. Connolly, L.G. Martini, D.P. Elder, M. Minekus, R. Havenaar, and E. Zeijdner Use of a gastro-intestinal model and Gastroplus™ for the prediction of in vivo performance Appl. Ther. Res. 6 1 2006 15 19
32. D.M. Omari, D. Johary, I.I. Salem, N. Najib, and A.A. Sallam Bioequivalence of two oral extended release formulations of ciprofloxacin tablets in healthymale volunteers under fed and fasting conditions J. Bioequivalence Bioavailab. 3 2 2011 38 42
33. B.S. Schug, E. Brendel, M. Wonnemann, D. Wolf, M. Wargenau, A. Dingler, and H.H. Blume Dosage form-related food interactions observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast Eur. J. Pharmacol. 58 2002 119 125
34. B.S. Schug, E. Brendel, E. Chantraine, D. Wolf, W. Martin, R. Schall, and H.H. Blume The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast Br. J. Clin. Pharmacol. 53 2002 582 588
35. A. Shah, M.-C. Liu, D. Vaughan, and A.H. Heller Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension J. Antimicrob. Chemother. 43 Suppl. A 1999 49 54
36. S. Souliman, S. Blanquet, E. Beysac, and J.-M. Cardot A level A in vitro/in vivo correlation in fasted and fed states using different methods: applied to solid immediate release oral dosage from Eur. J. Pharm. Sci. 27 2006 72 79
37. S. Souliman, E. Beyssac, J.-M. Cardot, S. Denis, and M. Alric Investigation of the biopharmaceutical behavior of theophylline hydrophilic matrix tablets using USP methods and an artificial digestive system Drug Dev. Ind. Pharm. 33 4 2007 475 483
38. S. Tenjarla, V. Romasanta, E. Zeijdner, R. Villa, and L. Moro Release of 5-aminosalicylate from an MMX mesalamine tablet during transit through a simulated gastrointestinal tract system Adv. Ther. 24 4 2007 826 840
39. J. Walravens, J. Brouwers, I. Spriet, J. Tack, P. Annaert, and P. Augustijns Effect of pH and co-medication on gastrointestinal absorption of posaconazole Clin. Pharmacokinet. 50 1 2011 725 734